Barrow D - Search Results

1

The biology of antihormone failure in breast cancer.

Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. Nicholson RI, et al. Among authors: barrow d. Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35. doi: 10.1023/a:1025467500433. Breast Cancer Res Treat. 2003. PMID: 14535532 Review.

2

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Knowlden JM, et al. Among authors: barrow d. Endocrinology. 2003 Mar;144(3):1032-44. doi: 10.1210/en.2002-220620. Endocrinology. 2003. PMID: 12586780

3

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Hutcheson IR, et al. Among authors: barrow d. Breast Cancer Res Treat. 2003 Sep;81(1):81-93. doi: 10.1023/A:1025484908380. Breast Cancer Res Treat. 2003. PMID: 14531500

4

Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nicholson RI, et al. Among authors: barrow d. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):346S-54S. doi: 10.1158/1078-0432.ccr-031206. Clin Cancer Res. 2004. PMID: 14734490

5

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Jordan NJ, et al. Among authors: barrow d. Breast Cancer Res Treat. 2004 Sep;87(2):167-80. doi: 10.1023/B:BREA.0000041623.21338.47. Breast Cancer Res Treat. 2004. PMID: 15377841

6

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Hiscox S, Morgan L, Barrow D, Dutkowskil C, Wakeling A, Nicholson RI. Hiscox S, et al. Among authors: barrow d. Clin Exp Metastasis. 2004;21(3):201-12. doi: 10.1023/b:clin.0000037697.76011.1d. Clin Exp Metastasis. 2004. PMID: 15387370

7

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Hiscox S, et al. Among authors: barrow d. Breast Cancer Res Treat. 2006 Jun;97(3):263-74. doi: 10.1007/s10549-005-9120-9. Epub 2005 Dec 7. Breast Cancer Res Treat. 2006. PMID: 16333527

8

Growth factor receptor interplay and resistance in cancer.

Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Jones HE, et al. Among authors: barrow d. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S45-51. doi: 10.1677/erc.1.01275. Endocr Relat Cancer. 2006. PMID: 17259558 Review.

9

Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI. Hutcheson IR, et al. Among authors: barrow d. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S89-97. doi: 10.1677/erc.1.01279. Endocr Relat Cancer. 2006. PMID: 17259562 Review.

10

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI. Hutcheson IR, et al. Among authors: barrow d. Breast Cancer Res. 2007;9(4):R50. doi: 10.1186/bcr1754. Breast Cancer Res. 2007. PMID: 17686159 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters